Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,623 across all filing types
Latest filing 2026-01-21 Transaction in Own Shar…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a 'Next Day Disclosure Return' (Form FF305) filed with the Hong Kong Stock Exchange. It explicitly details the repurchase of shares by RemeGen Co., Ltd. on 20 January 2026. According to the filing definitions, documents reporting the company buying back its own shares are classified as 'Transaction in Own Shares' (POS).
2026-01-21 English
ANNOUNCEMENT ON THE FIRST SHARE REPURCHASE AND THE COMPLETION OF THE SHARE REPURCHASE PLAN
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from RemeGen Co., Ltd. regarding the completion of a share repurchase plan. It details the number of shares repurchased, the price range, the total funds used, and the impact on the company's share structure. This falls directly under the category of 'Transaction in Own Shares' (POS), as it reports the company's buyback activity.
2026-01-21 English
ANNOUNCEMENT ON THE ADJUSTMENT TO THE UPPER LIMIT OF THE PRICE OF A SHARE REPURCHASE
Transaction in Own Shares Classification · 98% confidence The document is an official announcement from RemeGen Co., Ltd. regarding an adjustment to the upper price limit of a previously approved share repurchase plan. While it discusses share repurchases, it is not a report of a transaction that has already occurred (which would be POS), but rather a corporate governance and strategic update regarding the parameters of the repurchase program. Since it details a change in the terms of a capital-related activity (share repurchase plan), it falls under the category of Capital/Financing Update.
2026-01-15 English
INSIDE INFORMATION - Announcement on Signing a License Agreement with AbbVie
Capital/Financing Update Classification · 95% confidence The document is an official announcement from RemeGen Co., Ltd. regarding a significant licensing agreement with AbbVie for the drug RC148. It details the financial terms, scope of collaboration, and strategic impact of this transaction. While it involves a business agreement, it does not fit the specific criteria for M&A (which typically involves corporate mergers or takeovers) or other specialized categories. As it is a regulatory announcement regarding a material business development (inside information) that does not fall into a more specific category like 'TAR' or 'CAP', it is best classified as a general regulatory filing.
2026-01-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. It does not fit into categories like Annual Reports, Earnings Releases, or M&A activity. Since it is a recurring regulatory filing detailing share capital changes and movements, it falls under the 'Regulatory Filings' category.
2026-01-07 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2026-01-05 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.